HomepageARCT • NASDAQ
add
Arcturus Therapeutics Holdings Inc
$ 8,36
Na sluitingstijd:(1,56%)-0,13
$ 8,23
Gesloten: 10 apr, 17:10:29 GMT-4 · USD · NASDAQ · Disclaimer
Vorige slotkoers
$ 8,22
Dag-range
$ 8,19 - $ 8,43
Jaar-range
$ 5,86 - $ 24,14
Beurswaarde
237,62 mln. USD
Gem. volume
546,07K
Koers/winst
-
Dividendrendement
-
Primaire beurs
NASDAQ
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (USD) | dec 2025info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 7,20 mln. | -68,39% |
Bedrijfskosten | 14,03 mln. | 13,30% |
Netto inkomsten | -29,08 mln. | 3,09% |
Netto winstmarge | -404,10 | -206,60% |
Winst per aandeel | -1,03 | 7,21% |
EBITDA | -30,62 mln. | 5,99% |
Effectief belastingtarief | 0,01% | — |
Balans
Totale activa
Totale passiva
| (USD) | dec 2025info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 230,91 mln. | -2,58% |
Totale activa | 271,15 mln. | -21,19% |
Totale passiva | 57,16 mln. | -44,55% |
Totaal aandelenvermogen | 213,98 mln. | — |
Uitstaande aandelen | 28,42 mln. | — |
Koers-boekwaardeverhouding | 1,09 | — |
Rendement op activa | -28,28% | — |
Rendement op kapitaal | -31,98% | — |
Kasstroom
Nettomutatie in liquide middelen
| (USD) | dec 2025info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | -29,08 mln. | 3,09% |
Operationele kasstroom | -16,23 mln. | -5.613,73% |
Kasstroom uit beleggingen | 88,00K | — |
Kasstroom uit financiering | 11,69 mln. | 8.622,39% |
Nettomutatie in liquide middelen | -4,45 mln. | -2.867,33% |
Vrije kasstroom | 50,91 mln. | 434,06% |
Over
Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA, messenger RNA, gene editing RNA, DNA, antisense oligonucleotides, and microRNA.
The company develops RNA therapeutics for the treatment of rare diseases such as ornithine transcarbamylase deficiency, and respiratory diseases such as cystic fibrosis. Vaccine medicines include a vaccine candidate for COVID-19 and an influenza vaccine in the preclinical development phase. The vaccine for COVID-19 was authorised in Japan in 2023 and the European Union in 2025. Wikipedia
Opgericht
2013
Website
Werknemers
109
